Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Venus Remedies Ltd.
Change Company   
BSE Code 526953
ISIN Demat INE411B01019
Book Value 449.75
NSE Code VENUSREM
Dividend Yield % 0.00
Market Cap 6166.19
P/E 10.31
EPS 44.75
Face Value 10  
08-Jul-2025 Venus Remedies informs about confirmation certif...
22-May-2025 Venus Remedies secures Ukrainian GMP renewal
22-May-2025 Venus Remedies rises on securing Ukrainian GMP re...
17-Apr-2025 USFDA grants QIDP Designation to Venus Remedies’ ...
25-Feb-2025 Venus Remedies sings license agreement with lnfex...
25-Feb-2025 Venus Remedies informs about press release
25-Feb-2025 Venus Remedies jumps on singing license agreement...
31-Dec-2024 Venus Remedies gets GMP certification for antibio...
31-Dec-2024 Venus Remedies shines on getting GMP certificatio...
06-Dec-2024 Venus Remedies secures Marketing Authorization in...
30-Nov-2024 Venus Remedies gets nod to establish wholly owned...
05-Nov-2024 Venus Remedies secures Malaysian PIC/S GMP approv...
05-Nov-2024 Venus Remedies informs about press release
05-Nov-2024 Venus Remedies surges on securing Malaysian PIC/S...
24-Sep-2024 Venus Remedies informs about closure of trading w...
Page 1 of 1
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.